BTIG initiated Misonix with a Buy rating and a price target of $29, saying the company's expanded product range following its recent acquisition of Solsys Medical gives it "all the pieces" to generate sustainable growth of over 20%. The analyst also notes that Misonix offers the potential to address "large market opportunities", its larger sales force has the capacity to cross-sell, and its management brings a "history of consistent execution." Longer term, the analyst further notes that the company's Nexus platform can bring its ultrasonic technology into new markets like sports medicine and plastic surgery.